Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndrome

Bibliography

• World Health Organisation. Cardiovascular diseases. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/index.html. 2008. 13-8-2008
   Google Scholar
• Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326:242-50
   PubMed Web of Science ®Google Scholar
• Schneider DJ, Sobel BE. Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circ 2007;116:305-15
   PubMedGoogle Scholar
• Collaborative overview of randomised trials of antiplatelet therapy–I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936-42
   PubMed Web of Science ®Google Scholar
• An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993;329:673-82
   PubMed Web of Science ®Google Scholar
• Mehta S, Eikelboom JW, Yusuf S. Long-term management of unstable angina and non-Q-wave myocardial infarction. Eur Heart J 2008;2:E6-12
   Web of Science ®Google Scholar
• Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114:489S-510S
   PubMed Web of Science ®Google Scholar
• Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 2004;30:273-83
   PubMed Web of Science ®Google Scholar
• Mureebe L, Silver D. Heparin-induced thrombocytopenia: pathophysiology and management. Vasc Endovascular Surg 2002;36:163-70
   PubMedGoogle Scholar
• Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000;12(Suppl F):27F-32
   PubMedGoogle Scholar
• Witting JI, Bourdon P, Brezniak DV, et al. Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem J 1992;283(Pt 3):737-43
   PubMed Web of Science ®Google Scholar
• Robson RA. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000;12:F33-6
   PubMedGoogle Scholar
• Maraganore JM, Adelman BA. Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coron Artery Dis 1996;7:438-48
   PubMed Web of Science ®Google Scholar
• The Medicines company: Angiomax (bivalirudin) package insert. Cambridge, MA 2000
   Google Scholar
• Lui HK. Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention. J Invasive Cardiol 2000;12(Suppl F):41F-452
   PubMed Web of Science ®Google Scholar
• Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-9
   PubMed Web of Science ®Google Scholar
• Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-9
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63
   PubMed Web of Science ®Google Scholar
• Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16
   PubMed Web of Science ®Google Scholar
• Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007;369:907-19
   PubMed Web of Science ®Google Scholar
• Stone GW, Ware JH, Bertrand ME, et al, for the ACUITY Investigators: Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management One-Year Results From the ACUITY Trial. JAMA 2007;298:2497-506
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Yang Q, Pieper KS, et al. Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. J Gen Intern Med 2008;23:310-6
   PubMed Web of Science ®Google Scholar
• White HD, Chew DP, Hoekstra JW, et al. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008;51:1734-41
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler MD, Guagliumi G. Comparison of bivalirudin to heparin plus glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in acute myocardial infarction. 12 month outcome of the HORIZONS trial. - 2008
   Google Scholar
• Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292:1555-62
   PubMed Web of Science ®Google Scholar
• Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24:1815-23
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circ 2006;114:774-82
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008;51:690-7
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Quinlan DJ, Mehta SR, et al. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circ 2005;112:3855-67
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circ 2007;116:e148-304
   PubMed Web of Science ®Google Scholar
• Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-st-segment elevation acute coronary syndromes of the European society of cardiology. Eur Heart J 2007;28:1598-660
   PubMed Web of Science ®Google Scholar
• Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines Eighth Edition. Chest 2008;133:141S-59S
   PubMedGoogle Scholar
• Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007;49:1362-8
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30
   PubMed Web of Science ®Google Scholar
• Escobar GA, Cheng AM, Moore EE, et al. Stored packed red blood cell transfusion up-regulates inflammatory gene expression in circulating leukocytes. Ann Surg 2007;246:129-34
   PubMed Web of Science ®Google Scholar
• Murphy GJ, Reeves BC, Rogers CA, et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circ 2007;116:2544-52
   PubMed Web of Science ®Google Scholar
• Kunadian V, Zorkun C, Gibson WJ, et al. Transfusion associated microchimerism: a heretofore little recognized complication following transfusion. J Thromb Thrombolysis 2009;27(1):57-67
   PubMed Web of Science ®Google Scholar
• Campbell KR, Mahaffey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol 2000;12(Suppl F):14F-9
   PubMedGoogle Scholar
• Pinto DS, Stone GW, Shi C, et al. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol 2008;52:1758-68
   PubMed Web of Science ®Google Scholar
• White HD, Ohman EM, Lincoff AM, et al. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008;52:807-14
   PubMed Web of Science ®Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89
   PubMed Web of Science ®Google Scholar
• Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The thrombolysis in myocardial infarction. Am Heart J 2002;143:229-34
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002;143:847-53
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004;93:1092-6
   PubMed Web of Science ®Google Scholar